Darolutamide Extends Survival in Metastatic Prostate Cancer - NCI

Adding darolutamide (Nubeqa) to ADT and docetaxel improves survival in hormone-sensitive metastatic prostate cancer, results from the ARASENS trial show.

Patient education: Treatment for advanced prostate cancer (Beyond

New Prostate Cancer Treatment Approved in The U.S.

Darolutamide Delays the Spread of Some Prostate Cancers - NCI

PDF) 223P Overall survival (OS) results of phase III ARAMIS study

Nonmetastatic Castration-Resistant Prostate Cancer: Current

Prostate cancer - InDepth - SmartEngage

Are Bacteria and AI Taking the Stealth Out of Prostate Cancer

Cancers, Free Full-Text

PDF) Clinical Development of Darolutamide: A Novel Androgen

Understanding the Current Therapeutic Landscape for Advanced

Cancers, Free Full-Text

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival